相关实验视频
Updated: Jun 15, 2025
08:02
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
3.4K
阿洛伊-埃莫丁通过抑制巨细胞脱粒化来缓解过敏接触性皮肤炎
Yan Yang1, Jianmei Sun1, Huan You1
1School of Medicine, Nanjing University of Chinese Medicine, Nanjing, JS, China.
Immunology letters
|August 24, 2024
概括
阿洛伊埃莫丁有效治疗由乌鲁希醇诱导的过敏性接触性皮肤炎 (ACD) 和急性. 它通过抑制乳腺细胞脱粒,减少小鼠的炎症和皮肤病变来起作用.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尿沙醇引起的过敏性接触性皮肤炎 (ACD) 是一种皮肤疾病,其特征是炎症,和病变,通常与免疫系统失衡有关.
- 阿洛伊埃莫丁是一种来自传统药物的天然化合物,具有已知的抗炎和抗过敏特性.
研究的目的:
- 为了研究伊莫丁在缓解乌鲁希醇诱导的急性和过敏接触性皮肤炎方面的疗效.
- 阐明爱莫丁影响ACD炎症反应的机制.
主要方法:
- 鼠被暴露在urushiol中以诱导过敏接触性皮肤炎和急性.
- 进行了阿洛伊埃莫丁治疗,并评估了其对杆细胞脱粒和炎症性细胞因子的表达的影响.
- 分析了化学激素和细胞激素的表达 (CXCL1,CXCL2,CCL2,TSLP,TNF-α,IL-4,IL-6).
主要成果:
- 暴露于urushiol刺激了角质细胞释放化学因子和TNF-α,从而导致巨细胞的激活.
- 阿洛伊埃莫丁治疗显著抑制了皮肤病变中的巨细胞脱粒化.
- 阿洛伊埃莫丁抑制了关键的炎症性细胞因子的表达,包括互白素-4和互白素-6.
结论:
- 阿洛伊埃莫丁显示出对urushiol诱导的急性和过敏接触性皮肤炎的治疗潜力.
- 阿洛伊埃莫丁的抗炎作用是通过抑制巨细胞脱粒和减少促炎性细胞因子表达的介导.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
254
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
254
02:06Allergic Reactions
27.3K
Overview
27.3K
01:27Allergic Drug Reactions
824
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
824
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:19Antiasthma Drugs: Leukotriene Modifiers
259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
259